FDA panel endorses first-of-a-kind cancer blood test from Grail
📍 How it ended
{ "epilogue": "An FDA advisory committee voted in favor of approval for Grail's Galleri multi-cancer early detection test. The panel endorsed the benefits of the controversial blood test, helping it clear a crucial hurdle on the track to potential FDA approval." }
Epilogue added 36d ago, after coverage quieted.
Coverage (6)
-
-
-
-
-
-
Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval WSJ · 53d ago broke it first
What happened
- Velocity & Diffusion: Coverage escalated across 6 distinct news outlets with 6 published articles, achieving a live velocity of 4.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"FDA panel endorses first-of-a-kind cancer blood test from Grail" developed substantial multi-source reporting across the Business sector, tracked across 6 distinct newsrooms by Newsylist.
Key reporting was led by Reuters, PR Newswire, The Seattle Times and Scientific American. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 36d ago.
Questions people are asking
What drove coverage for FDA panel endorses first-of-a-kind cancer blood test from Grail?
Coverage spiked when 6 independent newsrooms published 6 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.